Abstract: Crystalline polymorphous forms of the rifaximin (INN) antibiotic named rifaximin ? and rifaximin ?, and a poorly crystalline form named rifaximin ? have been discovered. These forms are useful in the production of medicinal preparations for oral and topical use and can be obtained by means of a crystallization process carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by the addition of water at a determinate temperature and for a determinate period of time. The crystallization is followed by drying carried out under controlled conditions until a specific water content is reached in the end product.

Abstract: The present invention relates to rifaximin polymorphic forms ?, ? and ?, the processes for their preparation and the use thereof in the manufacture of medicinal preparations for the oral or topical route.

Abstract: The present invention is directed to a crystalline polymorph of bazedoxifene acetate, compositions containing the same, preparations thereof, and uses thereof.

Abstract: At the present invention relates to a new process for the preparation of the (S)-naproxen 4-nitrooxybutyl ester and to new intermediates obtained and used therein. The invention further relates to the use of the new intermediates for the manufacturing of pharmaceutically active compounds such as (S)-naproxen 4-nitrooxybutyl ester. The invention also relates to the use of (S)-naproxen 4-nitrooxybutyl ester prepared according to the process of the present invention for the manufacturing of a medicament for the treatment of pain.

Abstract: A process and new oxazolinic intermediates for the preparation of 4-(8-chloro-5,6-dihydro-11H-benzo-[5,6]-clohepta-[1,2-b]-pyridin-11-ylidene)-1-piperidinecarboxylic acid ethyl ester (loratadine) is described. The process starts from 2-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)-3-methyl-pyridine, a new intermediate to obtain loratadine. 2-(4,4-dimethyl-4,5-dihydrooxazol-2-yl)-3-methyl-pyridine is condensed with 3-chloro-benzyl-chloride and the resultant product is treated with Grignard reagent of 4-chloro-N-methyl-piperidine. [3-(2-(3-chloro-phenyl)-ethyl]-pyridin-2-yl]-1-(methyl-piperidin-4-yl)-methanone is obtained for subsequent hydrolysis. Starting from this last compound it is possible to obtain loratadine with known methods.

Abstract: An oxidation process for the preparation of intermediates useful in the synthesis of diarylpiridines is described. The oxidation of the thioether of formula III to give the sulfone of formula II is is carried out with a mixture of peracetic acid and hydrogen peroxide as oxidant, in the presence of methanesulphonic acid and in the absence of a catalylst.

Abstract: Crystalline polymorphous forms of the rifaximin (INN) antibiotic named rifaximin ? and rifaximin ?, and a poorly crystalline form named rifaximin ? have been discovered. These forms are useful in the production of medicinal preparations for oral and topical use and can be obtained by means of a crystallization process carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by the addition of water at a determinate temperature and for a determinate period of time. The crystallization is followed by drying carried out under controlled conditions until a specific water content is reached in the end product.

Abstract: A process for the purification of gabapentin by treatment of a crude aqueous gabapentin hydrochloride solution with a strong cationic ion exchange resin.

Abstract: Stable compositions containing gabapentin compositions, methods of preparing such compositions, and methods of using such compositions.

Abstract: An isomerization process of trans-5-fluoro-2-methyl-1-[p-(methylthio)benzyliden]inden-3-acetic acid for the treatment of sodium salt in methanol and in the presence of a base at 70±2° C. is described.

Abstract: A method for the removal of heavy metals from solutions of organic compounds by treatment with cysteine or with an N-acylcysteine is described. Organic compounds with a content of heavy metal, for example palladium, particularly low and suitable for the preparation of compounds with pharmacologic activity can be isolated from the resultant solutions.

Abstract: Process for the production of alkoxycarbonyldipeptides intermediates in the synthesis of the lisinopril which comprises protecting both amino functions of the L-lysine with an alkoxycarbonyl group, subsequently making the N-carboxyanhydride of the N6-[alkoxycarbonyl]-L-lysine by treatment with thionyl chloride and making the desired alkoxycarbonyldipeptide by reaction with L-proline in alkaline medium.

Abstract: Process for the production of alkoxycarbonyldipeptides intermediates in the synthesis of the lisinopril which comprises protecting both amino functions of the L-lysine with an alkoxycarbonyl group, subsequently making the N-carboxyanhydride of the N6-[alkoxycarbonyl]-L-lysine by treatment with thionyl chloride and making the desired alkoxycarbonyldipeptide by reaction with L-proline in alkaline medium.

Abstract: The process for the production of form I of anhydrous terazosin monohydrochloride consists of heating terazosin suspended in a mixture made by methanol and a solvent selected from C.sub.2 to C.sub.6, straight or branched alcohols, esters of C.sub.1 -C.sub.8 aliphatic carboxylic acids with straight or branched C.sub.1 to C.sub.8 alcohols, C.sub.3 to C.sub.8 aliphatic ketones, C.sub.4 to C.sub.8 straight branched or cyclic aliphatic ethers, aliphatic amides and aliphatic nitriles with a methanol solution of hydrochloric acid.

Abstract: The process for the production of the form I of the terazosin monohydrochloride anhydrous consists of treating at the boiling temperature terazosin monohydrochloride dihydrate with a mixture of methanol and a solvent selected from C.sub.2 -C.sub.6 straight or branched alcohols, the esters of the C.sub. -C.sub.8 carboxylic aliphatic acids with C.sub.1 -C.sub.8 straight or branched alcohols, C.sub.3 to C.sub.8 aliphatic ketones, C.sub.4 to C.sub.8 straight, branched or cyclic aliphatic ethers, aliphatic amides and the aliphatic nitriles.

Abstract: A process for the preparation of 5-amino-2,4,6-triiodoisophthalic acid dichloride by chlorinating 5-amino-2,4,6-triiodoisophthalic acid with thionyl chloride in the presence of a suitable solvent and of a tertiary amine salt or quaternary ammonium salt in a molar ratio from 1;1 to 1;2 with respect to 5-amino-2,4,6-triiodoisophathalic acid is described. 5-amino-2,4,6-triiodoisophthalic acid dichloride is an intermediate useful for the preparation of iodinated contrast agents.

Abstract: A process for manufacturing 1-(3-trifluoromethyl)phenyl-propan-2-one intermediate in the synthesis of the anorexic drug fenfluramine consists of reacting the diazonium salt of 3-trifluoromethylaniline with isopropenyl acetate in a polar solvent in the presence of a catalytic amount of a cuprous salt and, optionally, of a base and purifying the crude product through the bisulfite complex or distillation under vacuum.

Abstract: Process for the production of the isomers (R) and (S)-.alpha.-methyl-3-(trifluoromethyl)benzeneethanamine, the second being useful as intermediate in the synthesis of the anorexic drug dexfenfluramine (INN), which comprises carrying out a stereospecific reductive amination of 1-(3-trifluoromethyl)phenyl-2-propanone with (R) or (S)-.alpha.-methylbenzylamine under a hydrogen atmosphere in the presence of a catalyst and debenzylating the resulting diastereoisomer (R),(R) or (S),(S)-N-(1-phenylethyl)-.alpha.-methyl-3-(trifluoromethyl)benzeneethanam ine by treatment with hydrogen and a catalyst.

Abstract: A process is described for preparing a compound of the formula I: ##STR1## or a salt thereof; wherein X is a protecting group and R.sub.1, R.sub.2, R.sub.3 and R.sub.4 are each independently hydrogen, C.sub.1-6 alkyl or C.sub.1-6 perfluoroalkyl, R.sub.5 is hydrogen or when n is 1 R.sub.5 taken together with R.sub.3 comprises a double bond; m is 1, 2 or 3; n is 0 or 1, and p is 0, 1 or 2.

Abstract: New process for the synthesis of the antiinflammatory drug known as nabumetone that consists in reacting 2-acetyl-5-bromo-6-methoxynaphthalene with an alkyl acetate in presence of an alkaline alcoholate to get 4-(5-bromo-6-methoxy-2-naphthyl)-4-hydroxybut-3-en-2-one that by catalytic hydrogenation in a polar solvent and in presence of a base gives 4-(6-methoxy-2-naphthyl)butan-2-one known as nabumetone.